Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Cancer chemotherapy and pharmacology

Results: 26-50/1592

Authors: Koch, CJ Hahn, SM Rockwell, K Covey, JM McKenna, WG Evans, SM
Citation: Cj. Koch et al., Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitrolmidazoles, CANC CHEMOT, 48(3), 2001, pp. 177-187

Authors: Bahadori, HR Green, MR Catapano, CV
Citation: Hr. Bahadori et al., Synergistic interaction between topotecan and microtubule-interfering agents, CANC CHEMOT, 48(3), 2001, pp. 188-196

Authors: Sharma, RA Eatock, MM Twelves, CJ Brown, G McLelland, HR Clayton, KT O'Byrne, KJ Moyses, C Carmichael, J Steward, WP
Citation: Ra. Sharma et al., Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver, CANC CHEMOT, 48(3), 2001, pp. 197-201

Authors: Supko, JG Garcia-Carbonero, R Puchalski, TA Malspeis, L
Citation: Jg. Supko et al., Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs, CANC CHEMOT, 48(3), 2001, pp. 202-208

Authors: Finlay, IG Stewart, GJ Shirley, P Woolfe, S Pourgholami, MH Morris, DL
Citation: Ig. Finlay et al., Hepatic arterial and intravenous administration of 1,25-dihydroxyvitamin D-3-evidence of a clinically significant hepatic first-pass effect, CANC CHEMOT, 48(3), 2001, pp. 209-214

Authors: Thomas, RR Dahut, W Harold, N Grem, JL Monahan, BP Liang, M Band, RA Cottrell, J Llorens, V Smith, JA Corse, W Arbuck, SG Wright, J Chen, AP Hamilton, JM Allegra, CJ Takimoto, CH
Citation: Rr. Thomas et al., A phase I and pharmacologic study of 9-aminocamptothecin administered as a120-h infusion weekly to adult cancer patients, CANC CHEMOT, 48(3), 2001, pp. 215-222

Authors: O'Reilly, S Hartman, NR Bowling, KM Rowinsky, EK Donehower, RC Collins, J Strong, JM
Citation: S. O'Reilly et al., Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine, CANC CHEMOT, 48(3), 2001, pp. 223-228

Authors: Guminski, AD Harnett, PR deFazio, A
Citation: Ad. Guminski et al., Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia, CANC CHEMOT, 48(3), 2001, pp. 229-234

Authors: Salzer, W Widemann, B McCully, C Adamson, PC Balis, FM
Citation: W. Salzer et al., Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates, CANC CHEMOT, 48(3), 2001, pp. 235-240

Authors: Sloan, JA Atherton, P Reid, J Pilot, HC Erlichman, C Schaaf, L
Citation: Ja. Sloan et al., Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide, CANC CHEMOT, 48(3), 2001, pp. 241-249

Authors: Cavazos, CM Keir, ST Yoshinari, T Bigner, DD Friedman, HS
Citation: Cm. Cavazos et al., Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts, CANC CHEMOT, 48(3), 2001, pp. 250-254

Authors: Nardi, M De Marco, S Fabi, A Aloe, A Magnani, E Pacetti, U Carlini, P Ruggeri, EM Cognetti, F
Citation: M. Nardi et al., Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study, CANC CHEMOT, 48(3), 2001, pp. 255-258

Authors: Bhargava, P Marshall, JL Fried, K Williams, M Lefebvre, P Dahut, W Hanfelt, J Gehan, E Figuera, M Hawkins, MJ Rizvi, NA
Citation: P. Bhargava et al., Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer, CANC CHEMOT, 48(2), 2001, pp. 95-103

Authors: Takeda, K Negoro, S Takifuji, N Nitta, T Yoshimura, N Terakawa, K Fukuoka, M
Citation: K. Takeda et al., Dose escalation study of irinotecan combined with carboplatin for advancednon-small-cell lung cancer, CANC CHEMOT, 48(2), 2001, pp. 104-108

Authors: Olver, I Davy, M Luftner, D Park, SH Egorin, M Ellis, A Webster, L
Citation: I. Olver et al., A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer, CANC CHEMOT, 48(2), 2001, pp. 109-114

Authors: Nallani, SC Genter, MB Desai, PB
Citation: Sc. Nallani et al., Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel, CANC CHEMOT, 48(2), 2001, pp. 115-122

Authors: Fu, CH Martin-Aragon, S Weinberg, KI Ardi, VC Danenberg, PV Avramis, VI
Citation: Ch. Fu et al., Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein, CANC CHEMOT, 48(2), 2001, pp. 123-133

Authors: Reif, S Kingreen, D Kloft, C Grimm, J Siegert, W Schunack, W Jaehde, U
Citation: S. Reif et al., Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients, CANC CHEMOT, 48(2), 2001, pp. 134-140

Authors: Edelman, MJ Quam, H Mullins, B
Citation: Mj. Edelman et al., Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines, CANC CHEMOT, 48(2), 2001, pp. 141-144

Authors: Al Safarjalani, ON Zhou, XJ Naguib, FNM Goudgaon, NM Schinazi, RF el Kouni, MH
Citation: On. Al Safarjalani et al., Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio) acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy, CANC CHEMOT, 48(2), 2001, pp. 145-150

Authors: Herbst, RS Lynch, C Vasconcelles, M Teicher, BA Strauss, G Elias, A Anderson, I Zacarola, P Dang, NH Leong, T Salgia, R Skarin, AT
Citation: Rs. Herbst et al., Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial, CANC CHEMOT, 48(2), 2001, pp. 151-159

Authors: Papadopoulou, MV Ji, M Bloomer, WD
Citation: Mv. Papadopoulou et al., Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice, CANC CHEMOT, 48(2), 2001, pp. 160-168

Authors: Guo, PG Ma, JG Li, SL Guo, ZW Adams, AL Gallo, JM
Citation: Pg. Guo et al., Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model, CANC CHEMOT, 48(2), 2001, pp. 169-176

Authors: McLaren, BR Whitaker, D Robinson, BWS Lake, RA
Citation: Br. Mclaren et al., Expression and integrity of DNA topoisomerase II isoforms does not explaingeneric drug resistance in malignant mesothelioma, CANC CHEMOT, 48(1), 2001, pp. 1-8

Authors: Kovac, C Chie, L Morin, J Friedman, FK Robinson, R Chung, DL Kanovsky, M Flom, J Brandt-Rauf, PW Yamaizumi, Z Michl, J Pincus, MR
Citation: C. Kovac et al., Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation, CANC CHEMOT, 48(1), 2001, pp. 9-14
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>